Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 | P35367 | 4/20 | 0.65 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.51 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.49 |
| ▸ | IKBKB | O14920 | 1/20 | 0.48 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.46 |
| ▸ | PRKACA | P17612 | 1/20 | 0.46 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.46 |
| ▸ | PRKG1 | Q13976 | 1/20 | 0.46 |
| ▸ | PKN1 | Q16512 | 1/20 | 0.46 |
| ▸ | PKN2 | Q16513 | 1/20 | 0.46 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.46 |
| ▸ | CDC42BPA | Q5VT25 | 1/20 | 0.46 |
| ▸ | Q6ZSR9 | Q6ZSR9 | 1/20 | 0.46 |
| ▸ | BMP2K | Q9NSY1 | 1/20 | 0.46 |
| ▸ | CDC42BPB | Q9Y5S2 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | HTR6 | P50406 | 1/20 | 0.45 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30361750 | 0.87 | CYP3A4 (0.54) | HRH1ALDH1A1CYP3A4MAOB | |
| SCHEMBL14155651 | 0.87 | CYP3A4 (0.54) | HRH1ALDH1A1CYP3A4MAOB | |
| SCHEMBL13328988 | 0.86 | HRH1 (0.47) | HRH1ROCK1PRKCZALDH1A1CYP3A4 | |
| SCHEMBL14999402 | 0.83 | CYP3A4 (0.50) | HRH1ALDH1A1CYP3A4MAOB | |
| SCHEMBL1029569 | 0.83 | CYP3A4 (0.50) | HRH1ALDH1A1CYP3A4MAOB | |
| SCHEMBL30469288 | 0.83 | CYP3A4 (0.50) | HRH1ALDH1A1CYP3A4MAOB | |
| SCHEMBL29370524 | 0.83 | CYP3A4 (0.50) | HRH1ALDH1A1CYP3A4MAOB | |
| SCHEMBL12807780 | 0.83 | MAOB (0.52) | HRH1ROCK1HTR6MAOBHTR2C | |
| SCHEMBL13369995 | 0.81 | CYP3A4 (0.48) | HRH1ALDH1A1CYP3A4MAOB | |
| SCHEMBL13806374 | 0.81 | HRH1 (0.62) | HRH1ROCK1PRKCZIKBKBROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3564232-B1 | BMP-SIGNAL-INHIBITING COMPOUND | RIKEN (JP) | 2022-01-26 | — | — | EP | disclosed |
| EP-3354646-A1 | ISOINDOLINE COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | Celgene Corporation (US) | 2018-08-01 | — | — | EP | disclosed |
| EP-2985281-B1 | ISOINDOLINE COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | CELGENE CORP (US) | 2017-12-27 | — | — | EP | disclosed |
| US-9796698-B2 | Isoindoline compounds and methods of their use | CELGENE CORPORATION (US) | 2017-10-24 | — | — | US | disclosed |
| US-20170088538-A1 | ISOINDOLINE COMPOUNDS AND METHODS OF THEIR USE | CELGENE CORPORATION | 2017-03-30 | — | — | US | disclosed |
| US-9550766-B2 | Isoindoline compounds and methods of their use | CELGENE CORPORATION (US) | 2017-01-24 | — | — | US | disclosed |
| US-20160115161-A1 | ISOINDOLINE COMPOUNDS AND METHODS OF THEIR USE | CELGENE CORPORATION | 2016-04-28 | — | — | US | disclosed |
| EP-2985281-A2 | ISOINDOLINE COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | Celgene Corporation (US) | 2016-02-17 | — | — | EP | disclosed |
| US-9227954-B2 | Isoindoline compounds and methods of their use | CELGENE CORPORATION (US) | 2016-01-05 | — | — | US | disclosed |
| EP-2358697-B1 | ISOINDOLINE COMPOUNDS FOR USE IN THE TREATMENT OF CANCER. | CELGENE CORP (US) | 2015-10-21 | — | — | EP | disclosed |
| EP-1626958-B1 | (PIPERIDINYLOXY)PHENYL, (PIPERIDINYLOXY)PYRIDINYL, (PIPERIDINYLSULFANYL)PHENYL AND (PIPERIDINYLSULFANYL)PYRIDINYL COMPOUNDS AS 5-HT 1F AGONISTS | LILLY CO ELI (US) | 2012-06-27 | — | — | EP | disclosed |
| US-20120122865-A1 | ISOINDOLINE COMPOUNDS AND METHODS OF THEIR USE | CELGENE CORPORATION | 2012-05-17 | — | — | US | disclosed |
| US-8129375-B2 | Isoindoline compounds and methods of their use | CELGENE CORPORATION (US) | 2012-03-06 | — | — | US | disclosed |
| WO-2011142359-A1 | SPIRO COMPOUND AND DRUG FOR ACTIVATING ADIPONECTIN RECEPTOR | 日産化学工業株式会社 (JP) | 2011-11-17 | — | — | WO | disclosed |
| US-20100204227-A1 | ISOINDOLINE COMPOUNDS AND METHODS OF THEIR USE | CELGENE CORPORATION | 2010-08-12 | — | — | US | disclosed |
| US-7608629-B2 | (Piperidinyloxy)phenyl, (piperidinyloxy)pyridinyl, (piperidinylsulfanyl)phenyl and (piperidinylsulfanyl)pyridinyl compounds as 5-HT1F agonists | ELI LILLY AND COMPANY (US) | 2009-10-27 | — | — | US | disclosed |
| WO-2008128231-A1 | PYRIMIDINE DERIVATIVES | HUTCHISON MEDIPHARMA ENTERPRISES LIMITED (BS) | 2008-10-23 | — | — | WO | disclosed |
| US-20060211734-A1 | (Piperidinyloxy)phenyl, (piperidinyloxy)pyridinyl, (piperidinylsulfanyl)phenyl and (piperidinylsulfanyl)pyridinyl compounds as 5-ht1f agonists | ELILILLY AND COMPANY (US) | 2006-09-21 | — | — | US | disclosed |
| EP-1626958-A1 | (PIPERIDINYLOXY)PHENYL, (PIPERIDINYLOXY)PYRIDINYL, (PIPERIDINYLSULFANYL)PHENYL AND (PIPERIDINYLSULFANYL)PYRIDINYL COMPOUNDS AS 5-HT 1F AGONISTS | ELI LILLY AND COMPANY (US) | 2006-02-22 | — | — | EP | disclosed |
| WO-2004094380-A1 | (PIPERIDINYLOXY)PHENYL, (PIPERIDINYLOXY)PYRIDINYL, (PIPERIDINYLSULFANYL)PHENYL AND (PIPERIDINYLSULFANYL)PYRIDINYL COMPOUNDS AS 5-HT1F AGONISTS | ELI LILLY AND COMPANY (US) | 2004-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170088538-A1 | ISOINDOLINE COMPOUNDS AND METHODS OF THEIR USE | CPT1A, CYP11B2, NPC1 | HRH1 751/4885ROCK1 2036/4885PRKCZ 2947/4885 |
| US-20100204227-A1 | ISOINDOLINE COMPOUNDS AND METHODS OF THEIR USE | CPT1A, CYP11B2, NPC1 | HRH1 751/4885ROCK1 2036/4885PRKCZ 2947/4885 |
| US-20060211734-A1 | (Piperidinyloxy)phenyl, (piperidinyloxy)pyridinyl, (piperidinylsulfanyl)phenyl and (piperidinylsulfanyl)pyridinyl compounds as 5-ht1f agonists | HTR1A, HTR1F, HTR5A | HRH1 590/4885ROCK1 1916/4885PRKCZ 3056/4885 |
| US-20120122865-A1 | ISOINDOLINE COMPOUNDS AND METHODS OF THEIR USE | CPT1A, CYP11B2, NPC1 | HRH1 751/4885ROCK1 2036/4885PRKCZ 2947/4885 |
| US-20160115161-A1 | ISOINDOLINE COMPOUNDS AND METHODS OF THEIR USE | CPT1A, CYP11B2, NPC1 | HRH1 751/4885ROCK1 2036/4885PRKCZ 2947/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.